About the Company
Ironwood Pharmaceuticals, Inc is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea.By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide. By 2006 Microbia was starting to struggle with the different challenges and expenses of drug development, along with its industrial fermentation business and drug discovery efforts, and made the decision to split in two, with "Microbia Precision Engineering" focused on industrial applications led by Bailey and Microbia focused on drug discovery and development. Tate & Lyle invested $7M in the Microbia spinout and took a board seat in 2006. Microbia changed its name to Ironwood in 2008 and shortened the name of the industrial business to Microbia.By 2009, Ironwood had raised a total of $281M. In early 2010 Ironwood held its IPO, which priced at $11.25 a share, below the target price of $14. Later that year it sold its interests in Microbia to DSM for an undisclosed sum.Linaclotide (Linzess in the US and Mexico, and as Constella elsewhere), a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause, was approved in the US and Europe in 2012. Most of the marketing rights were licensed to Allergan and Astellas.It was developing a drug called IW-9179 or recanaclotide but abandoned it in 2016.BNC210 is an anxiolytic that Ironwood licensed and performed R&D on and then abandoned.In April 2018, the shares of Ironwood Pharmaceuticals closed up more than 10 percent on the news of biotech activist investor, Alex Denner joining its board.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IRWD News
5 Best Low Price Pharma Stocks To Invest In
As of Q4 2023 end, 30 out of the 933 hedge funds covered by Insider Monkey had bought and owned Ironwood Pharmaceuticals, Inc ...
Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up
Ironwood Pharmaceuticals, Inc. IRWD reported first-quarter 2023 adjusted earnings of 25 cents per share, which beat both the Zacks Consensus Estimate and our model estimates of 24 cents and 23 ...
First Week of June 21st Options Trading For Ironwood Pharmaceuticals (IRWD)
Investors in Ironwood Pharmaceuticals Inc (Symbol: IRWD) saw new options begin trading this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
Ironwood Pharmaceuticals Inc (IRWD) vs. Its Peers: A Comparison
The stock of Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has decreased by -1.14 when compared to last closing price of 7.88.Despite this, the company has seen a loss of -2.87% in its stock price over ...
Ironwood Pharmaceuticals, Inc. (IRWD)
BOSTON, February 29, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced positive topline results from its pivotal Phase III STARS trial ...
Ironwood Pharmaceuticals Inc Class A
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A
What Is a Stock Market Correction? Investors may be shaken by a drop of 10% or more in a stock market index, but corrections are par for the course.
Ironwood Pharmaceuticals Inc. Cl A
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Ironwood Pharmaceuticals, Inc. (IRWD)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
IRWD Ironwood Pharmaceuticals, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Loading the latest forecasts...